{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:30:53Z","timestamp":1790188253094,"version":"4.1.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00210-025-03826-4","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T09:40:05Z","timestamp":1738230005000},"page":"6597-6615","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lowering LDL cholesterol by PCSK9 inhibition: a new era of gene silencing, RNA, and alternative therapies"],"prefix":"10.1007","volume":"398","author":[{"given":"Mitali","family":"Paryani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay Kumar","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shital","family":"Butani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"issue":"5","key":"3826_CR1","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/nu12051440","volume":"12","author":"MP Adorni","year":"2020","unstructured":"Adorni MP, Zimetti F, Lupo MG, Ruscica M, Ferri N (2020) Naturally occurring PCSK9 inhibitors. Nutrients 12(5):1440. https:\/\/doi.org\/10.3390\/nu12051440","journal-title":"Nutrients"},{"key":"3826_CR2","unstructured":"Agency E, medicines (2020) Leqvio (inclisiran).\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/leqvio-epar-product-information_en.pdf. Accessed\u00a07 Jan 2025"},{"issue":"5","key":"3826_CR3","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S2213-8587(16)00074-7","volume":"4","author":"E Ajufo","year":"2016","unstructured":"Ajufo E, Rader DJ (2016) Recent advances in the pharmacological management of hypercholesterolaemia. Lancet Diabetes Endocrinol 4(5):436\u2013446. https:\/\/doi.org\/10.1016\/S2213-8587(16)00074-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"3826_CR4","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1001\/jamacardio.2017.3655","volume":"2","author":"A Arrieta","year":"2017","unstructured":"Arrieta A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K (2017) Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER Trial. JAMA Cardiol 2(12):1369\u20131374. https:\/\/doi.org\/10.1001\/jamacardio.2017.3655","journal-title":"JAMA Cardiol"},{"key":"3826_CR5","unstructured":"AstraZeneca (2022) AZD8233 reduced low-density lipoprotein cholesterol levels by 73% in patients with high-risk hypercholesterolemia in ETESIAN Phase IIb trial. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/azd8233-reduced-low-density-lipoprotein-cholesterol-levels-73-patients-high-risk-hypercholesterolemia-etesian-phase-iib-trial.html#. Accessed 24 July 2024"},{"key":"3826_CR6","doi-asserted-by":"publisher","unstructured":"Ballantyne CM, Banka P, Mendez G, Garcia R, Rosenstock J, Rodgers A,\u2026, Catapano AL (2023) Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616. J Am Coll Cardiol 81(16):1553\u20131564. https:\/\/doi.org\/10.1016\/j.jacc.2023.02.018","DOI":"10.1016\/j.jacc.2023.02.018"},{"key":"3826_CR7","doi-asserted-by":"publisher","unstructured":"Basak A, Ozed-williams B, Basak S (n.d.) Small molecule phytocompounds as promoters of LDL-receptor and PCSK9 Inhibition: potential role as non-statin based cardio-protective agents. In: Cardioprotective Natural Prod p. 277\u2013318. https:\/\/doi.org\/10.1142\/9789813231160_0008","DOI":"10.1142\/9789813231160_0008"},{"key":"3826_CR8","doi-asserted-by":"publisher","unstructured":"Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W,\u2026, Seidah NG (2004) NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 279(47):48865\u201348875. https:\/\/doi.org\/10.1074\/jbc.M409699200","DOI":"10.1074\/jbc.M409699200"},{"issue":"2","key":"3826_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.atherosclerosis.2011.04.018","volume":"216","author":"B Cariou","year":"2011","unstructured":"Cariou B, Le C, Costet P (2011) Clinical aspects of PCSK9. Atherosclerosis 216(2):258\u2013265. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.04.018","journal-title":"Atherosclerosis"},{"issue":"4","key":"3826_CR10","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.cell.2009.01.035","volume":"134","author":"RW Carthew","year":"2009","unstructured":"Carthew RW, Sontheir EJ (2009) Origins and Mechanisms of miRNAs and siRNAs. Cell 134(4):642\u2013655","journal-title":"Cell"},{"key":"3826_CR11","doi-asserted-by":"publisher","unstructured":"Catapano AL, Pirillo A, Norata GD (2020) New pharmacological approaches to target PCSK9. Curr Atheroscler Rep 22(7):https:\/\/doi.org\/10.1007\/s11883-020-00847-7","DOI":"10.1007\/s11883-020-00847-7"},{"issue":"2","key":"3826_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4330\/wjc.v9.i2.76","volume":"9","author":"R Chaudhary","year":"2017","unstructured":"Chaudhary R, Garg J, Shah N, Sumner A (2017) PCSK9 inhibitors: a new era of lipid lowering therapy. World J Cardiol 9(2):76. https:\/\/doi.org\/10.4330\/wjc.v9.i2.76","journal-title":"World J Cardiol"},{"key":"3826_CR13","doi-asserted-by":"publisher","unstructured":"Chieng D, Canovas R, Segan L, Sugumar H, Voskoboinik A, Prabhu S,\u2026, Kistler PM (2022) The impact of coffee subtypes on incident cardiovascular disease, arrhythmias, and mortality: long-term outcomes from the UK Biobank. Eur J Prev Cardiol 29(17), 2240\u20132249. https:\/\/doi.org\/10.1093\/eurjpc\/zwac189","DOI":"10.1093\/eurjpc\/zwac189"},{"issue":"12","key":"3826_CR14","doi-asserted-by":"publisher","first-page":"4582","DOI":"10.1039\/c7fo00562h","volume":"8","author":"HK Choi","year":"2017","unstructured":"Choi HK, Hwang JT, Nam TG, Kim SH, Min DK, Park SW, Chung MY (2017) Welsh onion extract inhibits PCSK9 expression contributing to the maintenance of the LDLR level under lipid depletion conditions of HepG2 cells. Food Funct 8(12):4582\u20134591. https:\/\/doi.org\/10.1039\/c7fo00562h","journal-title":"Food Funct"},{"issue":"12","key":"3826_CR15","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354(12):1264\u20131272. https:\/\/doi.org\/10.1056\/NEJMoa054013","journal-title":"N Engl J Med"},{"key":"3826_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.cca.2014.10.044","volume":"440","author":"CJ Cui","year":"2015","unstructured":"Cui CJ, Li S, Li JJ (2015) PCSK9 and its modulation. Clin Chim Acta 440:79\u201386. https:\/\/doi.org\/10.1016\/j.cca.2014.10.044","journal-title":"Clin Chim Acta"},{"issue":"10","key":"3826_CR17","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrcardio.2014.84","volume":"11","author":"RT Dadu","year":"2014","unstructured":"Dadu RT, Ballantyne CM (2014) Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol 11(10):563\u2013575. https:\/\/doi.org\/10.1038\/nrcardio.2014.84","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"3826_CR18","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1001\/jamacardio.2016.5395","volume":"2","author":"NR Desai","year":"2017","unstructured":"Desai NR, Giugliano RP, Wasserman SM, Gibbs JP, Liu T, Scott R, Sabatine MS (2017) Association between circulating baseline proprotein convertase subtilisin kexin type 9 levels and efficacy of evolocumab. JAMA Cardiol 2(5):556\u2013560. https:\/\/doi.org\/10.1001\/jamacardio.2016.5395","journal-title":"JAMA Cardiol"},{"issue":"5","key":"3826_CR19","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40256-022-00534-9","volume":"22","author":"NR Desai","year":"2022","unstructured":"Desai NR, Campbell C, Electricwala B, Petrou M, Trueman D, Woodcock F (2022) Cost effectiveness of inclisiran in atherosclerotic cardiovascular patients with elevated low - density lipoprotein cholesterol despite statin use\u202f: a threshold analysis. Am J Cardiovasc Drugs 22(5):545\u2013556. https:\/\/doi.org\/10.1007\/s40256-022-00534-9","journal-title":"Am J Cardiovasc Drugs"},{"issue":"6","key":"3826_CR20","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1161\/CIRCULATIONAHA.113.005925","volume":"129","author":"M Ding","year":"2014","unstructured":"Ding M, Bhupathiraju SN, Satija A, Van Dam RM, Hu FB (2014a) Long-term coffee consumption and risk of cardiovascular disease: a systematic review and a dose-response meta-analysis of prospective cohort studies. Circulation 129(6):643\u2013659. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.005925","journal-title":"Circulation"},{"key":"3826_CR21","doi-asserted-by":"publisher","unstructured":"Ding Q, Strong A, Patel KM, Ng SL, Gosis BS, Regan SN,\u2026, Musunuru K (2014) Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res 115(5):488\u2013492. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.304351","DOI":"10.1161\/CIRCRESAHA.115.304351"},{"issue":"3","key":"3826_CR22","doi-asserted-by":"publisher","first-page":"226","DOI":"10.4103\/jpcs.jpcs","volume":"6","author":"P Dua","year":"2020","unstructured":"Dua P, Reeta KH (2020) PCSK9 ( Proprotein Convertase Subtilisin \/ Kexin Type 9 ): A Narrative Review. J Pract Cardiovasc Sci 6(3):226\u201333. https:\/\/doi.org\/10.4103\/jpcs.jpcs","journal-title":"J Pract Cardiovasc Sci"},{"key":"3826_CR23","unstructured":"Eilat S, Oestraicher Y, Rabinkov A, Ohad D, Mirelman D, Battler A,\u00a0Eldar M,\u00a0Vered Z (1995) Alteration of lipid profile in hyperlipidemic rabbits by allicin, an active constituent of garlic. Coron Artery Dis 6(12):985\u2013990.\u00a0http:\/\/europepmc.org\/abstract\/MED\/8723021.\u00a0Accessed 10 Aug 2024"},{"key":"3826_CR24","doi-asserted-by":"publisher","unstructured":"Fan TY, Yang YX, Zeng QX, Wang XL, Wei W, Guo XX, \u2026 Hong B (2021) Structure\u2013activity relationship and biological evaluation of berberine derivatives as PCSK9 down-regulating agents. Bioorg Chem 113(February):104994. https:\/\/doi.org\/10.1016\/j.bioorg.2021.104994","DOI":"10.1016\/j.bioorg.2021.104994"},{"key":"3826_CR25","doi-asserted-by":"crossref","unstructured":"Galabova G, Brunner S, Winsauer G, Juno C, Wanko B, Mairgofer A, Luhrs P, Schneeberger A, von Bonin A, Mattner F, Schmidt W (2014) Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management. PLoS ONE 9(12):1\u201318.\u00a0https:\/\/journals.plos.org\/plosone\/article?id=https:\/\/doi.org\/10.1371\/journal.pone.0114469.\u00a0Accessed 5 Aug 2024","DOI":"10.1371\/journal.pone.0114469"},{"issue":"8","key":"3826_CR26","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.arcmed.2019.01.001","volume":"49","author":"R Garcia","year":"2018","unstructured":"Garcia R, Burkle J (2018) New and future parenteral therapies for the management of lipid disorders. Arch Med Res 49(8):538\u2013547. https:\/\/doi.org\/10.1016\/j.arcmed.2019.01.001","journal-title":"Arch Med Res"},{"key":"3826_CR27","doi-asserted-by":"publisher","unstructured":"Gennemark P, Walter K, Clemmensen N, Reki\u0107 D, Nilsson CAM, Kn\u00f6chel J,\u2026, Davies N (2021) An oral antisense oligonucleotide for PCSK9 inhibition. Sci Transl Med 13(593):eabe9117. https:\/\/doi.org\/10.1126\/scitranslmed.abe9117","DOI":"10.1126\/scitranslmed.abe9117"},{"key":"3826_CR28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cca.2014.07.008","volume":"437","author":"YL Guo","year":"2014","unstructured":"Guo YL, Zhang W, Li JJ (2014) PCSK9 and lipid lowering drugs. Clin Chim Acta 437:66\u201371. https:\/\/doi.org\/10.1016\/j.cca.2014.07.008","journal-title":"Clin Chim Acta"},{"issue":"May","key":"3826_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20944\/preprints202205.0290.v1","volume":"9","author":"JK Gupta","year":"2022","unstructured":"Gupta JK, Kumar S, Singh K, Singh K, Meenakshi K (2022) PCSK9 Inhibitors. Pharmacol Ther Potential 9(May):1\u201317. https:\/\/doi.org\/10.20944\/preprints202205.0290.v1","journal-title":"Pharmacol Ther Potential"},{"key":"3826_CR30","doi-asserted-by":"publisher","unstructured":"Gustafsen C, Olsen D, Vilstrup J, Lund S, Reinhardt A, Wellner N,\u2026, Glerup S (2017) Heparan sulfate proteoglycans present PCSK9 to the LDL receptor. Nature Commun 8(1):1\u201314. https:\/\/doi.org\/10.1038\/s41467-017-00568-7","DOI":"10.1038\/s41467-017-00568-7"},{"key":"3826_CR31","doi-asserted-by":"publisher","unstructured":"Hofherr A, Schumi J, Reki\u0107 D, Kn\u00f6chel J, Nilsson CAM, Rudvik A,\u2026, Carlsson BCL (2022) ETESIAN: A phase 2B study of the efficacy, safety and tolerability of AZD8233, a PCSK9-targeted antisense oligonucleotide, in patients with dyslipidemia. Atherosclerosis 355:28. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.06.075","DOI":"10.1016\/j.atherosclerosis.2022.06.075"},{"issue":"Suppl_1","key":"3826_CR32","doi-asserted-by":"publisher","first-page":"A974","DOI":"10.1161\/circ.144.suppl_1.9747","volume":"144","author":"A Hofherr","year":"2021","unstructured":"Hofherr A, NilssonRekicKnoechelGoldwaterHanKusnirOvercashWatersWhiteHurt-CamejoWernevikIsakssonWangBhanotRyden CADJRDJJSMAELRYSKM, CBC (2021) Safety, pharmacokinetics and pharmacodynamics of multiple ascending doses of AZD8233, targeting PCSK9, in patients with dyslipidemia. Circulation 144(Suppl_1):A974","journal-title":"Circulation"},{"issue":"2","key":"3826_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.tibs.2006.12.008","volume":"32","author":"JD Horton","year":"2007","unstructured":"Horton JD, Cohen JC, Hobbs HH (2007) Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 32(2):71\u201377. https:\/\/doi.org\/10.1016\/j.tibs.2006.12.008","journal-title":"Trends Biochem Sci"},{"key":"3826_CR34","unstructured":"Ionis Pharmaceuticals (2022) Press release, https:\/\/ir.ionispharma.com\/news-releases\/news-release-details\/ionis-provides-update-development-program-evaluating-pcsk9.\u00a0Accessed 13 Aug 2024"},{"key":"3826_CR35","doi-asserted-by":"publisher","unstructured":"Jing Y, Hu T, Lin C, Xiong Q, Liu F, Yuan J,\u2026, Wang R (2019) Resveratrol downregulates PCSK9 expression and attenuates steatosis through estrogen receptor \u03b1-mediated pathway in L02\u202fcells. Eur J Pharmacol 855, 216\u2013226. https:\/\/doi.org\/10.1016\/j.ejphar.2019.05.019","DOI":"10.1016\/j.ejphar.2019.05.019"},{"key":"3826_CR36","doi-asserted-by":"publisher","unstructured":"Kawakami R, Nozato Y, Nakagami H, Ikeda Y, Shimamura M, Yoshida S, Sun J, Kawano T, Takami Y, Noma T, Rakugi H, Minamino T, Morishita R (2018) Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin\/kexin type 9 (PCSK9) epitope in mice. PLoS ONE 13(2):e0191895. https:\/\/doi.org\/10.1371\/journal.pone.0191895","DOI":"10.1371\/journal.pone.0191895"},{"issue":"3","key":"3826_CR37","first-page":"63","volume":"6","author":"CE Kosmas","year":"2018","unstructured":"Kosmas CE, Munoz Estrella A, Sourlas A, Silverio D, Hilario E, Montan PD (2018) Inclisiran: a new promising agent in the manage- ment of hypercholesterolemia Diseases. Dis 6(3):63","journal-title":"Dis"},{"issue":"2017","key":"3826_CR38","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ijcard.2018.04.122","volume":"267","author":"R Kumar","year":"2018","unstructured":"Kumar R, Tonkin A, Liew D, Zomer E (2018) The cost-effectiveness of PCSK9 inhibitors - the Australian healthcare perspective. Int J Cardiol 267(2017):183\u2013187. https:\/\/doi.org\/10.1016\/j.ijcard.2018.04.122","journal-title":"Int J Cardiol"},{"issue":"8","key":"3826_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11883-019-0792-8","volume":"21","author":"A Langsted","year":"2019","unstructured":"Langsted A, Nordestgaard BG (2019) Antisense oligonucleotides targeting lipoprotein(a). Curr Atheroscler Rep 21(8):1\u20137. https:\/\/doi.org\/10.1007\/s11883-019-0792-8","journal-title":"Curr Atheroscler Rep"},{"issue":"3","key":"3826_CR40","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s11239-016-1364-1","volume":"42","author":"J Latimer","year":"2016","unstructured":"Latimer J, Batty JA, Neely RDG, Kunadian V (2016) PCSK9 inhibitors in the prevention of cardiovascular disease. J Thromb Thrombolysis 42(3):405\u2013419. https:\/\/doi.org\/10.1007\/s11239-016-1364-1","journal-title":"J Thromb Thrombolysis"},{"key":"3826_CR41","doi-asserted-by":"publisher","unstructured":"Lebeau PF, Byun JH, Platko K, Saliba P, Sguazzin M, MacDonald ME,\u2026, Austin RC (2022) Caffeine blocks SREBP2-induced hepatic PCSK9 expression to enhance LDLR-mediated cholesterol clearance. Nat Commun 13(1). https:\/\/doi.org\/10.1038\/s41467-022-28240-9","DOI":"10.1038\/s41467-022-28240-9"},{"issue":"2","key":"3826_CR42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/jmf.2020.0029","volume":"24","author":"JM Le\u00f3n-Mart\u00ednez","year":"2021","unstructured":"Le\u00f3n-Mart\u00ednez JM, Mart\u00ednez-Abundis E, Gonz\u00e1lez-Ortiz M, P\u00e9rez-Rubio KG (2021) Effect of berberine plus bezafibrate administration on the lipid profile of patients with mixed dyslipidemia: a pilot clinical trial. J Med Food 24(2):111\u2013115. https:\/\/doi.org\/10.1089\/jmf.2020.0029","journal-title":"J Med Food"},{"key":"3826_CR43","doi-asserted-by":"publisher","unstructured":"Lindholm MW, Elm\u00e9n J, Fisker N, Hansen HF, Persson R, M\u00f8ller MR,\u2026, Koch T (2012) PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Ther 20(2):376\u2013381. https:\/\/doi.org\/10.1038\/mt.2011.260","DOI":"10.1038\/mt.2011.260"},{"issue":"1\u20132","key":"3826_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/protein\/gzq097","volume":"24","author":"D Lipov\u0161ek","year":"2011","unstructured":"Lipov\u0161ek D (2011) Adnectins: engineered target-binding protein therapeutics. Protein Eng des Sel 24(1\u20132):3\u20139. https:\/\/doi.org\/10.1093\/protein\/gzq097","journal-title":"Protein Eng des Sel"},{"key":"3826_CR45","doi-asserted-by":"publisher","unstructured":"Masagalli JN, BasavanaGowda MK, Chae HS, Choi WJ (2021) Synthesis of moracin C and Its derivatives with a 2-arylbenzofuran motif and evaluation of their PCSK9 inhibitory effects in HepG2 cells. Molecules 26(5):1327. https:\/\/doi.org\/10.3390\/molecules26051327","DOI":"10.3390\/molecules26051327"},{"key":"3826_CR46","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.fob.2014.08.003","volume":"4","author":"M Mbikay","year":"2014","unstructured":"Mbikay M, Sirois F, Simoes S, Mayne J, Chr\u00e9tien M (2014) Quercetin-3-glucoside increases low-density lipoprotein receptor ( LDLR ) expression, attenuates proprotein convertase subtilisin \/ kexin 9 ( PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture. FEBS Open Bio 4:755\u2013762. https:\/\/doi.org\/10.1016\/j.fob.2014.08.003","journal-title":"FEBS Open Bio"},{"key":"3826_CR47","unstructured":"Merck (n.d.) Merck\u2019s MK-0616, an investigational oral PCSK9 Inhibitor, significantly reduced LDL-C in patients with hypercholesterolemia in phase 2b study.\u00a0https:\/\/www.merck.com\/news\/mercks-mk-0616-an-investigational-oral-pcsk9-inhibitor-significantly-reduced-ldl-c-in-patients-with-hypercholesterolemia-in-phase-2b-study\/. Accessed 20 Sept 2024"},{"key":"3826_CR48","doi-asserted-by":"publisher","unstructured":"Mitchell T, Chao G, Sitkoff D, Lo F, Monshizadegan H, Meyers D,\u2026, Parker RA (2014) Pharmacologic profile of the adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering. J Pharmacol Exp Therapeutics 350(2):412\u2013424. https:\/\/doi.org\/10.1124\/jpet.114.214221","DOI":"10.1124\/jpet.114.214221"},{"key":"3826_CR49","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.phrs.2017.03.023","volume":"120","author":"AA Momtazi","year":"2017","unstructured":"Momtazi AA, Banach M, Pirro M, Katsiki N, Sahebkar A (2017) Regulation of PCSK9 by nutraceuticals. Pharmacol Res 120:157\u2013169. https:\/\/doi.org\/10.1016\/j.phrs.2017.03.023","journal-title":"Pharmacol Res"},{"issue":"11","key":"3826_CR50","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1002\/ptr.4646","volume":"26","author":"J Moon","year":"2012","unstructured":"Moon J, Lee SM, Do HJ, Cho Y, Chung JH, Shin MJ (2012) Quercetin up-regulates LDL receptor expression in HepG2 cells. Phytother Res 26(11):1688\u20131694. https:\/\/doi.org\/10.1002\/ptr.4646","journal-title":"Phytother Res"},{"key":"3826_CR51","doi-asserted-by":"publisher","unstructured":"Musunuru K, Chadwick AC, Mizoguchi T, Garcia SP, Denizio JE, Reiss CW,\u2026, Kathiresan S (2021) In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 593(May). https:\/\/doi.org\/10.1038\/s41586-021-03534-y","DOI":"10.1038\/s41586-021-03534-y"},{"key":"3826_CR52","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/j.ihj.2023.12.011","volume":"76","author":"T Nair","year":"2024","unstructured":"Nair T (2024) Role of PCSK9 inhibitors in the management of dyslipidaemia. Indian Heart J 76:S44\u2013S50. https:\/\/doi.org\/10.1016\/j.ihj.2023.12.011","journal-title":"Indian Heart J"},{"key":"3826_CR53","doi-asserted-by":"publisher","unstructured":"Nawaka N, Wanmasae S, Makarasen A, Dechtrirat D, Techasakul S, Jeenduang N (2022) Allicin and capsaicin ameliorated hypercholesterolemia by upregulating LDLR and downregulating PCSK9 expression in HepG2 cells. Int J Molecular Sci 23(22). https:\/\/doi.org\/10.3390\/ijms232214299","DOI":"10.3390\/ijms232214299"},{"issue":"4","key":"3826_CR54","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.tips.2013.01.010","volume":"34","author":"GD Norata","year":"2013","unstructured":"Norata GD, Tibolla G, Catapano AL (2013) Gene silencing approaches for the management of dyslipidaemia. Trends Pharmacol Sci 34(4):198\u2013205. https:\/\/doi.org\/10.1016\/j.tips.2013.01.010","journal-title":"Trends Pharmacol Sci"},{"key":"3826_CR55","doi-asserted-by":"publisher","unstructured":"Pan Y, Zhou Y, Wu H, Chen X, Hu X, Zhang H,\u2026, Liao Y (2017) A therapeutic Peptide vaccine against PCSK9. Sci Rep 7(1):1\u201310. https:\/\/doi.org\/10.1038\/s41598-017-13069-w","DOI":"10.1038\/s41598-017-13069-w"},{"issue":"2","key":"3826_CR56","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/10942910601113327","volume":"10","author":"MS Rahman","year":"2007","unstructured":"Rahman MS (2007) Allicin and other functional active components in garlic: health benefits and bioavailability. Int J Food Prop 10(2):245\u2013268. https:\/\/doi.org\/10.1080\/10942910601113327","journal-title":"Int J Food Prop"},{"issue":"3","key":"3826_CR57","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jacc.2018.04.054","volume":"72","author":"JS Review","year":"2018","unstructured":"Review JS, Cannon CP, Journal J, Moc CME (2018) The evolving future of PCSK9 inhibitors. J Am Coll Cardiol 72(3):314\u2013329. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.054","journal-title":"J Am Coll Cardiol"},{"key":"3826_CR58","doi-asserted-by":"publisher","unstructured":"Sabatine MS (n.d.) PCSK9 inhibitors: clinical evidence and implementation. Nat Rev Cardiol. https:\/\/doi.org\/10.1038\/s41569-018-0107-8","DOI":"10.1038\/s41569-018-0107-8"},{"issue":"11\u201312","key":"3826_CR59","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.nut.2016.04.007","volume":"32","author":"A Sahebkar","year":"2016","unstructured":"Sahebkar A, Serban MC, Gluba-Brz\u00f3zka A, Mikhailidis DP, Cicero AF, Rysz J, Banach M (2016) Lipid-modifying effects of nutraceuticals: an evidence-based approach. Nutrition 32(11\u201312):1179\u20131192. https:\/\/doi.org\/10.1016\/j.nut.2016.04.007","journal-title":"Nutrition"},{"issue":"4","key":"3826_CR60","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nbt.2842","volume":"32","author":"JD Sander","year":"2014","unstructured":"Sander JD, Joung JK (2014) CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 32(4):347\u2013350. https:\/\/doi.org\/10.1038\/nbt.2842","journal-title":"Nat Biotechnol"},{"key":"3826_CR61","doi-asserted-by":"publisher","unstructured":"Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, B\u00e9langer Jasmin S, Stifani S,\u2026, Chr\u00e9tien M (2003) The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Nat Acad Sci U. S. A 100(3):928\u2013933. https:\/\/doi.org\/10.1073\/pnas.0335507100","DOI":"10.1073\/pnas.0335507100"},{"issue":"3","key":"3826_CR62","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1210\/endrev\/bnab035","volume":"43","author":"NG Seidah","year":"2022","unstructured":"Seidah NG, Prat A (2022) The multifaceted biology of PCSK9. Endocr Rev 43(3):558\u2013582. https:\/\/doi.org\/10.1210\/endrev\/bnab035","journal-title":"Endocr Rev"},{"key":"3826_CR63","doi-asserted-by":"publisher","unstructured":"Seidah NG (2017) The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol. Global Cardiol Sci Pract 2017(1). https:\/\/doi.org\/10.21542\/gcsp.2017.2","DOI":"10.21542\/gcsp.2017.2"},{"key":"3826_CR64","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000655","author":"Z Siddiqui","year":"2024","unstructured":"Siddiqui Z, Frishman W (2024) New oral PCSK9 inhibitor: \u201cMK-0616.\u201d Cardiol Rev. https:\/\/doi.org\/10.1097\/CRD.0000000000000655","journal-title":"Cardiol Rev"},{"key":"3826_CR65","doi-asserted-by":"publisher","unstructured":"Sindi AAA (2023) Genetics, safety, cost\u2010effectiveness, and accessibility of injectable lipid\u2010lowering agents: a narrative review. J Lipids 2023(1):2025490. https:\/\/doi.org\/10.1155\/2023\/2025490","DOI":"10.1155\/2023\/2025490"},{"key":"3826_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11883-014-0482-5","volume":"17","author":"S Singh","year":"2015","unstructured":"Singh S, Bittner V (2015) Familial hypercholesterolemia \u2014 epidemiology, diagnosis, and screening. Curr Atheroscler Rep 17:1\u20138. https:\/\/doi.org\/10.1007\/s11883-014-0482-5","journal-title":"Curr Atheroscler Rep"},{"issue":"17","key":"3826_CR67","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.3390\/jcm10173828","volume":"10","author":"A Smith","year":"2021","unstructured":"Smith A, Johnson D, Banks J, Keith SW, Karalis DG (2021) Trends in pcsk9 inhibitor prescriptions before and after the price reduction in patients with atherosclerotic cardiovascular disease. J Clin Med 10(17):3828. https:\/\/doi.org\/10.3390\/jcm10173828","journal-title":"J Clin Med"},{"issue":"12","key":"3826_CR68","doi-asserted-by":"publisher","first-page":"A1372","DOI":"10.1016\/s0735-1097(14)61372-3","volume":"63","author":"EA Stein","year":"2014","unstructured":"Stein EA, Kasichayanula S, Turner T, Kranz T, Arumugam U, Biernat L, Lee J (2014) Ldl cholesterol reduction with Bms-962476, an adnectin inhibitor of Pcsk9: results of a single ascending dose study. J Am Coll Cardiol 63(12):A1372. https:\/\/doi.org\/10.1016\/s0735-1097(14)61372-3","journal-title":"J Am Coll Cardiol"},{"key":"3826_CR69","doi-asserted-by":"publisher","unstructured":"Stein EA, Turner T, Biernat L, Dimova D, Zhou R, Dai M,\u2026, Mitchell T (2019) Low density lipoprotein cholesterol reduction and safety with Lib003, an anti-proprotein convertase subtilisin\/kexin type 9 fusion protein: results of a randomized, double-blind, placebo-controlled, single ascending dose study. J Am Coll Cardiol 73(9):1714. https:\/\/doi.org\/10.1016\/s0735-1097(19)32320-4","DOI":"10.1016\/s0735-1097(19)32320-4"},{"key":"3826_CR70","doi-asserted-by":"publisher","unstructured":"Stein E, Toth P, Butcher MB, Kereiakes D, Magnu P, Bays H,\u2026, Turner TA (2019) Safety, tolerability and Ldl-C reduction with a novel anti-Pcsk9 recombinant fusion protein (Lib003): results of a randomized, double-blind, placebo-controlled, phase 2 study. Atheroscler 287(2019):e7. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.06.019","DOI":"10.1016\/j.atherosclerosis.2019.06.019"},{"issue":"34","key":"3826_CR71","doi-asserted-by":"publisher","first-page":"8983","DOI":"10.1021\/acs.jafc.8b02696","volume":"66","author":"GG Sui","year":"2018","unstructured":"Sui GG, Xiao HB, Lu XY, Sun ZL (2018) Naringin activates AMPK resulting in altered expression of SREBPs, PCSK9, and LDLR to reduce body weight in obese C57BL\/6J mice. J Agric Food Chem 66(34):8983\u20138990. https:\/\/doi.org\/10.1021\/acs.jafc.8b02696","journal-title":"J Agric Food Chem"},{"issue":"11","key":"3826_CR72","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1002\/mnfr.201400366","volume":"58","author":"M Tai","year":"2014","unstructured":"Tai M, Chen P, Chen P, Wu M, Ho C, Yen J (2014) Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells. Mol Nutr Food Res 58(11):2133\u20132145. https:\/\/doi.org\/10.1002\/mnfr.201400366","journal-title":"Mol Nutr Food Res"},{"key":"3826_CR73","unstructured":"Therapeutics V (2024) VERVE 101 & VERVE 102.\u00a0https:\/\/www.vervetx.com\/our-programs\/verve-101-102. Accessed 15\u00a0Aug 2024"},{"key":"3826_CR74","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.yrtph.2017.07.025","volume":"89","author":"D Turnbull","year":"2017","unstructured":"Turnbull D, Rodricks JV, Mariano GF, Chowdhury F (2017) Caffeine and cardiovascular health. Regul Toxicol Pharmacol 89:165\u2013185. https:\/\/doi.org\/10.1016\/j.yrtph.2017.07.025","journal-title":"Regul Toxicol Pharmacol"},{"key":"3826_CR75","unstructured":"US FDA (2021) LEQVIO\u00ae (inclisiran) injection, for subcutaneous use.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214012lbl.pdf.\u00a0Accessed 29 Sept 2023"},{"key":"3826_CR76","unstructured":"Verve Therapeutics (2024) Verve therapeutics announces updates on its PCSK9 program. 2\u20133. https:\/\/ir.vervetx.com\/news-releases\/news-release-details\/verve-therapeutics-announces-updates-its-pcsk9-program. Accessed 29 Sept"},{"issue":"5","key":"3826_CR77","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1161\/ATVBAHA.116.307227","volume":"36","author":"X Wang","year":"2016","unstructured":"Wang X, Raghavan A, Chen T, Qiao L, Zhang Y, Ding Q, Musunuru K (2016) CRISPR-Cas9 targeting of PCSK9 in human hepatocytes in vivo - Brief report. Arterioscler Thromb Vasc Biol 36(5):783\u2013786. https:\/\/doi.org\/10.1161\/ATVBAHA.116.307227","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3826_CR78","doi-asserted-by":"publisher","unstructured":"Wang Y, Liu Z (2019) PCSK9 inhibitors: novel therapeutic strategies for lowering LDL- cholesterol. 165\u2013176. https:\/\/doi.org\/10.2174\/1389557518666180423111442","DOI":"10.2174\/1389557518666180423111442"},{"issue":"3","key":"3826_CR79","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.tcm.2019.05.007","volume":"30","author":"BA Warden","year":"2020","unstructured":"Warden BA, Fazio S, Shapiro MD (2020) The PCSK9 revolution: current status, controversies, and future directions. Trends Cardiovasc Med 30(3):179\u2013185. https:\/\/doi.org\/10.1016\/j.tcm.2019.05.007","journal-title":"Trends Cardiovasc Med"},{"key":"3826_CR80","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.cca.2014.01.043","volume":"431","author":"NQ Wu","year":"2014","unstructured":"Wu NQ, Li JJ (2014) PCSK9 gene mutations and low-density lipoprotein cholesterol. Clin Chim Acta 431:148\u2013153. https:\/\/doi.org\/10.1016\/j.cca.2014.01.043","journal-title":"Clin Chim Acta"},{"issue":"October","key":"3826_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcvm.2021.764038","volume":"8","author":"XD Xia","year":"2021","unstructured":"Xia XD, Peng ZS, Gu HM, Wang M, Wang GQ, Zhang DW (2021) Regulation of PCSK9 expression and function: mechanisms and therapeutic Implications. Front Cardiovasc Med 8(October):1\u201313. https:\/\/doi.org\/10.3389\/fcvm.2021.764038","journal-title":"Front Cardiovasc Med"},{"key":"3826_CR82","doi-asserted-by":"publisher","unstructured":"Xiao Y, Ba Z, Pang S, Liu D, Wang H, Liang H,\u2026, Yuan J (2022) PCSK9 inhibitor: safe alternative to fill the treatment gap in statin-limited conditions? Rev Cardiovasc Med 23(11). https:\/\/doi.org\/10.31083\/j.rcm2311380","DOI":"10.31083\/j.rcm2311380"},{"issue":"7","key":"3826_CR83","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.biopha.2008.06.035","volume":"63","author":"W-W Xing","year":"2009","unstructured":"Xing W-W, Wu J-Z, Jia M, Du J, Zhang H, Qin L-P (2009) Effects of polydatin from Polygonum cuspidatum on lipid profile in hyperlipidemic rabbits. Biomed Pharmacother 63(7):457\u2013462","journal-title":"Biomed Pharmacother"},{"key":"3826_CR84","doi-asserted-by":"publisher","unstructured":"Zhang C, Xiang D, Zhao Q, Jiang S, Wang C, Yang H, \u2026 Liao D (2022) Curcumin nicotinate decreases serum LDL cholesterol through LDL receptor-mediated mechanism. Eur J Pharmacol 931(October 2021):175195. https:\/\/doi.org\/10.1016\/j.ejphar.2022.175195","DOI":"10.1016\/j.ejphar.2022.175195"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-03826-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-03826-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-03826-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T10:51:00Z","timestamp":1748602260000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-03826-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":84,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3826"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-03826-4","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]},"assertion":[{"value":"6 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}